AC Immune AG reports results for the quarter ended September 30 - Earnings Summary

AC Immune AG

04/11/2026 13:45

AC Immune AG ACIU.OQ reported a quarterly adjusted loss of 13 rappen​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -16 rappen.  The mean expectation of four analysts for the quarter was for a loss of 16 rappen per share. Wall Street expected results to range from -20 rappen to -13 rappen per share.
Revenue rose 245.5% to CHF3.24 million from a year ago; analysts expected CHF202.55 thousand. 
AC Immune AG's reported EPS for the quarter was a loss of 13 rappen​.
The company reported a quarterly loss of CHF8.75 million.
AC Immune AG shares had fallen by 20.2% this quarter and lost 33.4% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts was unchanged in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is  "buy."
Wall Street's median 12-month price target for AC Immune AG is $9.47, about 77.9% above its last closing price of $2.09
This summary was machine generated from LSEG data November 4 at 01:45 p.m. UTC. ​All figures in Swiss francs unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Sep. 30 2026 
-0.16
-0.13
Beat
Jun. 30 2026 
-0.11
0.02
Beat
Mar. 31 2026 
-0.15
-0.15
Met
Dec. 31 2025 
-0.17
-0.13
Beat